Arnica is one of Europe's most widely used topical anti-inflammatory herbs, with positive monographs from Commission E, ESCOP, and EMA. Its active sesquiterpene lactones (primarily helenalin) inhibit NF-kB activation and provide genuine anti-inflammatory, analgesic, and anti-edema effects. A landmark 204-patient RCT showed topical arnica gel was non-inferior to 5% ibuprofen gel for hand osteoarthritis. However, internal use is TOXIC (helenalin is a potent cytotoxin), and topical use carries a real risk of allergic contact dermatitis, particularly in individuals sensitive to Compositae (Asteraceae) plants. The distinction between evidence-based topical phytotherapy and homeopathic arnica (highly diluted, different framework) is important.

Topical capsaicin, derived from Capsicum peppers, has the most thoroughly characterized molecular mechanism of any herb in this module: it activates TRPV1 receptors on nociceptive nerve fibers, leading to initial stimulation followed by defunctionalization (not merely "substance P depletion," as was previously taught). It holds EMA "well-established use" status for muscle pain and Commission E/ESCOP approval for musculoskeletal and neuropathic pain. Available in concentrations from 0.025% to 8% (high-concentration prescription patch), it represents a genuine pharmaceutical-grade phytotherapeutic with robust evidence across osteoarthritis, neuropathic pain, and muscular pain.

Topical comfrey root extract is one of the best-studied herbal topical treatments for musculoskeletal conditions, with large, well-designed RCTs demonstrating superiority to diclofenac gel for ankle sprains and a 54.7% pain reduction in knee OA. The German product Kytta-Salbe (comfrey root fluid extract ointment) has a robust clinical trial program. However, internal use is ABSOLUTELY CONTRAINDICATED due to hepatotoxic pyrrolizidine alkaloids (PAs), and even topical use is time-limited (4-6 weeks maximum). Modern pharmaceutical products are PA-depleted, making topical use considerably safer than crude preparations, but the PA stigma has overshadowed the genuinely strong topical evidence base.

Devil's Claw is one of the best-studied herbal anti-inflammatories in the European phytotherapy tradition, with 14+ clinical trials supporting its use in osteoarthritis and low back pain. At doses providing >=50 mg harpagoside daily, it has demonstrated non-inferiority to diacerhein (for OA) and rofecoxib (for low back pain). It is widely prescribed in Germany and France but remains virtually unknown in US clinical practice, representing one of the most significant gaps between European and American phytotherapy.

Boswellia serrata (Indian frankincense) is an increasingly important anti-inflammatory herb with a growing evidence base in osteoarthritis, particularly knee OA. Its unique mechanism -- dual inhibition of 5-LOX and NF-kB, distinct from the COX pathway targeted by NSAIDs -- makes it a complementary rather than duplicative therapeutic option. Multiple RCTs with proprietary extracts (5-Loxin, Aflapin) show significant improvements in pain and function, with onset as early as 7 days. However, unlike most other herbs in this module, Boswellia lacks a full EMA herbal monograph, and its European regulatory position is less developed than its Ayurvedic tradition and modern clinical evidence would warrant.

Meadowsweet (Filipendula ulmaria) is historically significant as the plant from which aspirin derived its name -- "a-spirin" from "Spiraea," the old genus name for meadowsweet. The flowers and aerial parts contain salicylaldehyde, methyl salicylate, and salicin, along with flavonoids (notably spiraeoside) and tannins (rugosins). It holds EMA traditional use status for supportive treatment of common cold and as adjuvant for mild joint pain, but lacks Commission E or ESCOP monographs. No clinical trials exist for meadowsweet monotherapy. Paradoxically, despite its salicylate content, meadowsweet has been traditionally used to soothe the stomach -- in contrast to aspirin's well-known gastric irritation. This gastroprotective effect is attributed to its tannin and mucilage content, which may buffer the salicylate effects. Drug interactions with NSAIDs and anticoagulants are possible due to salicylate content.

Rosehip (Rosa canina) powder has emerged as a promising nutraceutical for osteoarthritis, supported by a meta-analysis of three RCTs (Christensen et al. 2008) showing a small-to-moderate effect on pain (ES 0.37) and an NNT of 6. The proposed active constituent is a galactolipid called GOPO, which has demonstrated anti-inflammatory and antioxidant properties in vitro. ESCOP has published a monograph supporting use in osteoarthritis. The EMA/HMPC has a traditional use monograph (as a vitamin C source and for mild joint complaints). Commission E published a negative monograph for rosehip pseudo-fruit, citing insufficient evidence at the time. The clinical evidence is modest but consistent -- all three key trials (Warholm 2003, Rein 2004, Winther 2005) showed benefits over placebo. However, the evidence base is limited by small sample sizes, short durations, and sponsorship by a single manufacturer. Rosehip is distinct from other musculoskeletal herbs in that its mechanism appears to involve galactolipid-mediated inhibition of leukocyte chemotaxis rather than direct COX/LOX inhibition.

Stinging nettle leaf has Commission E, ESCOP, and EMA recognition as an adjuvant in the treatment of arthritis and rheumatic conditions. Its anti-inflammatory mechanism centers on NF-kB pathway inhibition, TNF-alpha/IL-1beta suppression, and COX/LOX modulation via caffeic acid derivatives and flavonoids. Clinical evidence is more limited than for Devil's Claw or Willow Bark, consisting mainly of small trials and the distinctive practice of urtication (direct application of fresh nettle stings to painful joints). It serves best as an adjuvant therapy rather than a standalone treatment, and is notable for its excellent safety profile and nutritional density.

Willow Bark holds EMA "well-established use" status for low back pain -- the highest evidence tier available for herbal medicines in Europe. At 240 mg salicin/day, it demonstrated non-inferiority to rofecoxib (Vioxx) 12.5 mg/day in a head-to-head RCT for low back pain, at roughly 40% lower cost. Critically, willow bark is NOT simply "natural aspirin": it does not acetylate COX enzymes, has a broader mechanism of action, and produces far less GI toxicity. Despite this evidence, it remains rarely used in US clinical practice.